Drug Profile
Atorvastatin/choline-fenofibrate - Chong Kun Dang
Alternative Names: Atorvastatin calcium trihydrate/choline fenofibrate; CKD-337; Fenofibrate/atorvastatin - Chong Kun DangLatest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Amides; Antihyperlipidaemics; Chlorobenzenes; Ethanolamines; Fibric acid derivatives; Fluorobenzenes; Heptanoic acids; Pyrroles
- Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 27 Oct 2020 No development reported - Phase-III for Dyslipidaemias in South Korea (PO)
- 07 Nov 2017 Chong Kun Dang completes a phase I trial for Dyslipidaemias (In volunteers) in South Korea (NCT03382756)
- 16 Oct 2017 Chong Kun Dang initiates enrolment in a phase I trial for Dyslipidaemias (In volunteers) in South Korea (NCT03382756)